Have you relapsed on, or become refractory to a Btki drug such as ibrutinib, or the bcl-2i venetoclax?

[bkoffman]

Upcoming CLL Society webinar featuring Dr. Ian Flinn. Have you relapsed on, or become refractory to a Btki drug such as ibrutinib, or the bcl-2i venetoclax? These drugs have radically improved how CLL is treated. However, when patients relapse or become refractory to these, the approved PI3Kinase inhibitors duvelisib or idelalisib, and the still-experimental umbralisib offer potent and potentially helpful third options. Side effects of PI3ks have made some patients apprehensive. However, if properly managed, many CLL patients could reap benefits from these effective medications. "Frontload" your knowledge about PI3K inhibitors!

Dr. Ian Flinn: Revisiting PI3K Inhibitors for the Treatment of CLL: Are They Living Up to Their Promise? Thursday, August 26, 202110:00 AM PT, 11:00 AM MT, 12:00 PM CT, 1:00 PM ET (Duration 60 minutes)

cllsociety.org/cll-society-...

[Jm954 Administrator]

AndreaJo is this of interest to you and your husband?

[bkoffman CLL CURE Hero in reply to Jm954]

Important option beyond venetoclax and BTKis

[LynnB1947]

I'll be joining y'all from M D Anderson where I will be sitting in the waiting room between appointments from 12 pm - 1pm.

(7 years now on ibrutinib)

[Sushibruno in reply to LynnB1947]

🙂👍